Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016
Published Jun 15, 2016
67 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )
- The report reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics and enlists all their major and minor projects
- The report assesses Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )
- Identify potential new clients or partners in the target demographic

  
Source:
Document ID
GMDHC8198IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview71
Therapeutics Development81
  Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview81
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics under Development by Companies91
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Pipeline Products Glance104
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
  Unknown Stage Products131
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Products under Development by Companies141
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Companies Involved in Therapeutics Development1511
  Alexion Pharmaceuticals, Inc.151
  AngioChem Inc.161
  ArmaGen Inc.171
  Bioasis Technologies Inc.181
  Green Cross Corporation191
  Inventiva201
  JCR Pharmaceuticals Co., Ltd.211
  Laboratorios Del Dr. Esteve S.A.221
  RegenxBio Inc.231
  Sangamo BioSciences, Inc.241
  Shire Plc251
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Assessment269
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3519
  AGT-182 Drug Profile352
  EGT-301 Drug Profile371
  idursulfase Drug Profile382
  idursulfase beta Drug Profile402
  JR-032 Drug Profile421
  JR-141 Drug Profile431
  MTf-I2S Drug Profile441
  MTfp-I2S Drug Profile451
  odiparcil Drug Profile461
  pentosan polysulfate sodium Drug Profile471
  Recombinant Enzymes for Pompe, Fabry and Hunter Diseases Drug Profile481
  Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II Drug Profile491
  RGX-121 Drug Profile502
  SB-913 Drug Profile522
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Dormant Projects541
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Discontinued Products551
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Product Development Milestones5610
  Featured News &Press Releases561
    Apr 19, 2016: Preclinical Data from REGENXBIO s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene &Cell Therapy 19th Annual Meeting561
    Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome571
    Jul 31, 2015: Bioasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome571
    Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital581
    Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire591
    Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial591
    Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome601
    Sep 18, 2014: Bioasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation611
    Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome621
    Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria621
    Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182631
    Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press631
    Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome641
    Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase651
    Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome651
Appendix662
  Methodology661
  Coverage661
  Secondary Research661
  Primary Research661
  Expert Panel Validation661
  Contact Us661
  Disclaimer671

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-II-MPS-II-Hunter-Syndrome-Pipeline-Review-H1-2016-2088-15952>
  
APA:
Global Markets Direct - Market Research. (2016). Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mucopolysaccharidosis-II-MPS-II-Hunter-Syndrome-Pipeline-Review-H1-2016-2088-15952>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.